



March 26, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.  
Representative: Hidetoshi Segi, President and Representative Director  
(Code: 4527 TSE Prime)  
Contact: Masaya Saito, Vice President and CFO  
(TEL:06-6758-8223)

**Notice Regarding the Repurchase of Shares**  
**(Repurchase of Shares pursuant to Provisions of Articles of Incorporation**  
**in accordance with Article 459, Paragraph 1 of the Companies Act)**

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that pursuant to a resolution of the Board of Directors as of March 26, 2026, the Company has resolved to repurchase its own shares as follows, pursuant to the provision of Article 459, Paragraph 1 of the Companies Act thereof.

1. Reason for Repurchase of Shares

The Company will conduct a share repurchase to improve capital efficiency and enable the flexible execution of capital policies.

2. Matters regarding Repurchase

(1)	Class of Shares Repurchased	Common stock
(2)	Total Number of Shares Repurchased	Up to 1,500,000 shares (0.66 % of total number of issued shares (excluding treasury stock))
(3)	Total Repurchase Price	Up to 3 billion yen
(4)	Period of Repurchase	From March 27, 2026 to December 31, 2026
(5)	Repurchase Method	Market purchases on the Tokyo Stock Exchange conducted

(Reference)

Status of Treasury Stock as of March 26, 2026

-	Total Issued Shares (Including Treasury Stock):	236,178,310 shares
-	Number of Treasury Stock:	10,213,970 shares
	Total Issued Shares (Excluding Treasury Stock):	225,964,340 shares